Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers

Data presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics FPI-2068 demonstrates anti-tumor activity in colorectal and lung tumor xenograft mouse models FPI-2068, developed as part of collaboration agreement with AstraZeneca, received…